Welcome to LookChem.com Sign In|Join Free
  • or
3,4-DIFLUOROHYDROCINNAMIC ACID is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

161712-75-0

Post Buying Request

161712-75-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

161712-75-0 Usage

Chemical Properties

White powder

Check Digit Verification of cas no

The CAS Registry Mumber 161712-75-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,7,1 and 2 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 161712-75:
(8*1)+(7*6)+(6*1)+(5*7)+(4*1)+(3*2)+(2*7)+(1*5)=120
120 % 10 = 0
So 161712-75-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H8F2O2/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1,3,5H,2,4H2,(H,12,13)

161712-75-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H26185)  3-(3,4-Difluorophenyl)propionic acid, 98%   

  • 161712-75-0

  • 1g

  • 366.0CNY

  • Detail
  • Alfa Aesar

  • (H26185)  3-(3,4-Difluorophenyl)propionic acid, 98%   

  • 161712-75-0

  • 5g

  • 1213.0CNY

  • Detail

161712-75-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 3,4-DIFLUOROHYDROCINNAMIC ACID

1.2 Other means of identification

Product number -
Other names 3-(3,4-difluorophenyl)propanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:161712-75-0 SDS

161712-75-0Relevant academic research and scientific papers

Method for selective reduction α, β - unsaturated carbonyl compound carbon-carbon double bond (by machine translation)

-

Paragraph 0059-0062, (2020/06/17)

The invention discloses a method for selectively reducing carbon-carbon double bonds in α and β - unsaturated carbonyl compounds, which comprises the following steps of adding α, β - unsaturated carbonyl compounds shown in formula (I) in an electrolysis system and reducing α and β - unsaturated carbonyl compounds with carbonyl-conjugated carbon-carbon double bonds through an electrochemical cathodic reduction reaction. Compared with the reported method, the method disclosed by the invention does not use a metal catalyst and an external oxidant; and the reaction raw material and the electrolyte are low in price, nontoxic and tasteless, simple and convenient in post-treatment. (by machine translation)

PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATION

-

Paragraph 00328; 00331, (2020/05/06)

Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)

P2X4 RECEPTOR MODULATING COMPOUNDS

-

Paragraph 00252, (2015/06/25)

Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.

Bicyclic cyclohexylamines and their use as nmda receptor antagonists

-

Page 53, (2010/02/06)

Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 161712-75-0